• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series.

作者信息

Kim Jenna May, Materin Miguel A, Sznol Mario, Kluger Harriet M, Weiss Sarah, Chow Jessica, Stoessel Kathleen, Kombo Ninani, Del Priore Lucian, Pointdujour-Lim Renelle

机构信息

Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, Connecticut.

Duke Eye Center Ophthalmic Oncology, Duke University School of Medicine, Durham, North Carolina.

出版信息

Ophthalmology. 2019 Jul;126(7):1058-1062. doi: 10.1016/j.ophtha.2019.01.031. Epub 2019 Feb 6.

DOI:10.1016/j.ophtha.2019.01.031
PMID:30735682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6933747/
Abstract
摘要

相似文献

1
Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series.免疫疗法的眼科免疫相关不良事件：单中心病例系列
Ophthalmology. 2019 Jul;126(7):1058-1062. doi: 10.1016/j.ophtha.2019.01.031. Epub 2019 Feb 6.
2
Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.一名接受伊匹木单抗和纳武单抗检查点抑制剂免疫治疗的患者出现广泛的亚急性皮肤型红斑狼疮。
Dermatol Online J. 2019 Oct 15;25(10):13030/qt4md713j8.
3
Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.黑色素瘤皮肤癌治疗后出现的白毛症。
Ophthalmic Plast Reconstr Surg. 2019 Sep/Oct;35(5):e121-e122. doi: 10.1097/IOP.0000000000001451.
4
Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.联合免疫检查点抑制剂与单药治疗相比的安全性：系统评价和荟萃分析。
Cancer Invest. 2020 Mar;38(3):150-157. doi: 10.1080/07357907.2020.1714053. Epub 2020 Feb 16.
5
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.免疫检查点抑制剂相关骨骼免疫不良反应：一项重要的病例系列研究。
J Immunother Cancer. 2018 Oct 11;6(1):104. doi: 10.1186/s40425-018-0417-8.
6
Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.免疫检查点抑制剂癌症免疫疗法相关免疫介导反应的药物警戒评估。
Pharmacotherapy. 2017 Nov;37(11):1383-1390. doi: 10.1002/phar.2035. Epub 2017 Oct 26.
7
Immunotherapy-induced autoimmune hypophysitis.免疫疗法诱发的自身免疫性垂体炎。
J Oncol Pharm Pract. 2019 Jan;25(1):217-220. doi: 10.1177/1078155217727142. Epub 2017 Aug 21.
8
[Histoseminar on inflammatory bowel diseases (IBD): Case n 04].[炎症性肠病（IBD）组织学研讨会：病例编号04]
Ann Pathol. 2017 Aug;37(4):298-301. doi: 10.1016/j.annpat.2017.06.005. Epub 2017 Jul 19.
9
Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.免疫检查点抑制剂相关噬血细胞性淋巴组织细胞增生症：一项描述性病例研究及文献综述
Br J Haematol. 2020 Jun;189(5):985-992. doi: 10.1111/bjh.16630. Epub 2020 Apr 3.
10
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.免疫检查点抑制剂治疗后并发神经结节病的迟发性发作。
J Immunother Cancer. 2018 Jul 31;6(1):77. doi: 10.1186/s40425-018-0390-2.

引用本文的文献

1
Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database.基于FAERS数据库的伊匹木单抗和纳武单抗联合治疗相关不良事件的不成比例性分析。
Sci Rep. 2025 Jul 1;15(1):21055. doi: 10.1038/s41598-025-07287-w.
2
Immune checkpoint inhibitor-associated Vogt-Koyanagi-Harada-like syndrome: A descriptive systematic review.免疫检查点抑制剂相关的类葡萄膜炎-小柳原田综合征：一项描述性系统评价。
J Ophthalmic Inflamm Infect. 2025 May 12;15(1):44. doi: 10.1186/s12348-025-00484-8.
3
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors.免疫检查点抑制剂眼部免疫相关不良事件的共识性疾病定义。
J Immunother Cancer. 2025 Apr 8;13(4):e011049. doi: 10.1136/jitc-2024-011049.
4
Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis.在癌症免疫治疗背景下，类固醇节省型免疫抑制剂对肿瘤预后的影响，重点关注黑色素瘤：系统文献综述与荟萃分析
Front Immunol. 2024 Dec 16;15:1499478. doi: 10.3389/fimmu.2024.1499478. eCollection 2024.
5
Case report: Longitudinal evaluation and treatment of a melanoma-associated retinopathy patient.病例报告：一名黑色素瘤相关性视网膜病变患者的纵向评估与治疗
Front Med (Lausanne). 2024 Sep 10;11:1445180. doi: 10.3389/fmed.2024.1445180. eCollection 2024.
6
Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database.眼科免疫相关不良事件与生存的关系：来自真实世界数据库的结果。
Am J Ophthalmol. 2024 Dec;268:348-359. doi: 10.1016/j.ajo.2024.08.044. Epub 2024 Sep 11.
7
Clinical Patterns and Factors Contributing to Ophthalmic and Otologic Events Associated With Immune Checkpoint Inhibitors: A Narrative Review.与免疫检查点抑制剂相关的眼科和耳科事件的临床模式及促成因素：一项叙述性综述
Cureus. 2024 Aug 10;16(8):e66611. doi: 10.7759/cureus.66611. eCollection 2024 Aug.
8
Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients.免疫检查点抑制剂相关的颅神经受累：对136例患者的系统文献综述
J Neurol. 2024 Oct;271(10):6514-6525. doi: 10.1007/s00415-024-12660-2. Epub 2024 Sep 3.
9
Periocular granulomatous inflammatory lesions mimicking conjunctival melanoma recurrence in the setting of systemic nivolumab treatment.在接受全身性纳武单抗治疗的情况下，出现类似结膜黑色素瘤复发的眼周肉芽肿性炎性病变。
Am J Ophthalmol Case Rep. 2024 Feb 18;36:102025. doi: 10.1016/j.ajoc.2024.102025. eCollection 2024 Dec.
10
-TRPM1 autoantibody-positive unilateral melanoma associated retinopathy (MAR) triggered by immunotherapy recapitulates functional and structural details of -associated congenital stationary night blindness.由免疫疗法引发的TRPM1自身抗体阳性单侧黑色素瘤相关性视网膜病变（MAR）重现了相关先天性静止性夜盲的功能和结构细节。
Am J Ophthalmol Case Rep. 2024 Jul 5;36:102098. doi: 10.1016/j.ajoc.2024.102098. eCollection 2024 Dec.

本文引用的文献

1
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
2
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.美国食品药品监督管理局批准概要：纳武单抗治疗伊匹单抗治疗后进展的不可切除或转移性黑色素瘤。
Clin Cancer Res. 2017 Jul 15;23(14):3484-3488. doi: 10.1158/1078-0432.CCR-16-0712. Epub 2017 Jan 13.
3
Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation.环孢素治疗与纳武单抗相关的干眼症：一例进展为角膜穿孔的病例
Cornea. 2016 Mar;35(3):399-401. doi: 10.1097/ICO.0000000000000724.
4
Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome.双侧药物（伊匹单抗）诱发的葡萄膜炎、脉络膜炎及浆液性视网膜脱离，提示伏格特-小柳-原田综合征。
Retin Cases Brief Rep. 2012 Fall;6(4):423-6. doi: 10.1097/ICB.0b013e31824f7130.
5
Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort.转移性黑色素瘤：前瞻性队列研究中，自身抗体的自发出现是一个良好的预后因素。
J Eur Acad Dermatol Venereol. 2013 Jan;27(1):92-6. doi: 10.1111/j.1468-3083.2011.04364.x. Epub 2011 Dec 7.